Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that IDH1 p.R132H status confers therapeutic sensitivity to Ivosidenib in patients with Cholangiocarcinoma.
This statement is based on a regulatory approval from the Health Canada:
TIBSOVO (ivosidenib) monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.